Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has today announced that its wholly owned medical devices subsidiary, Designer Diagnostics, will conduct clinical trials for its Tuberculosis (TB) and Nontuberculous Mycobacterium (NTM) diagnostic Test Kits at National Jewish Medical and Research Center in Denver, Colorado.
“These clinical trials are extremely important for Designer Diagnostics, as they are the final step required by the FDA before applying for regulatory approval,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “As one of the leading Tuberculosis research centers in the world, National Jewish Medical and Research Center provides the ideal environment for conducting such trials,” he added.
The Test Kits are designed to provide rapid identification and sensitivity testing of TB and NTM. The clinical trials at National Jewish Medical and Research Center will validate the efficacy of the Test Kits for use with TB and NTM patients as well as for the use with environmental testing.
“We will be working closely with Dr. Leonid Heifets, one for the leading researchers of TB and NTM disease detection in the world, to develop the appropriate trial protocols and perform the clinical trials,” explained Neil Roth, President of Designer Diagnostics. “Along with Dr. Heifets, we will be working with Dr. Charles Daley, the Director of Infectious Disease at National Jewish, to conduct additional trials in Africa and South America,” he concluded
One of the major advantages of the Designer Diagnostics Test Kits is the ability for developing countries to easily integrate these Test Kits into laboratory settings that do not offer modern technological resources. In addition, the Designer Diagnostics Test Kits do not require refrigeration, offer a longer shelf life, and are less expensive than current test kit technologies.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The clinical trials at National Jewish Medical and Research Center should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.